Executive Leadership

Bonnie Anderson

Cofounder and Chief Executive Officer Bonnie Anderson is the cofounder and Chief Executive Officer of Veracyte, formed in 2008. Her career spans more than 25 years in regulated diagnostics and life science markets where she has led both early-stage businesses as well as mature, global enterprises. Prior to Veracyte, Ms. Anderson provided strategic consulting services to venture capital firms and early-stage businesses following 18 years in leadership positions at Beckman Coulter, including heading the company’s global cellular analysis franchises in hematology and flow cytometry. As Vice President of the intrapreneurial start-up Immunomics Operations she successfully positioned the company’s novel MHC tetramer technology as a vehicle for drug and vaccine developers to monitor ex-vivo immune response. She currently serves as a member of the Board of Trustees of Keck Graduate Institute of Applied Life Sciences and on the advisory board for BayBio. She has also served on the boards of Thymed, GmbH and Women in Biotechnology.

Chris Hall

Chief Commercial Officer Chris Hall joined Veracyte in 2010 as Chief Commercial Officer. Mr. Hall most recently served as a Senior Vice President of Celera Corporation. Prior to this, Mr. Hall held several executive positions at Berkeley HeartLab (BHL; acquired by Celera in 2007), including Chief Clinical Operations Officer and Vice President, Marketing. During his time at BHL, Mr. Hall led the commercialization of several proprietary genetic tests, as well as the launch of a new sample collection platform and was instrumental in repositioning the company from a specialty laboratory for advanced lipid blood tests to a cardiovascular disease management company. Mr. Hall has also held management and sales positions with Asimba, Kenan Systems, and Symmetrix. Mr. Hall holds a Bachelor of Arts degree from DePauw University in Greencastle, Indiana and an M.B.A. from Harvard University.

Giulia C. Kennedy, PhD

Chief Scientific Officer, Senior Vice President of Research and Development Giulia C. Kennedy joined the company in April 2008 and serves as Chief Scientific Officer. Prior to joining Veracyte, Dr. Kennedy led the Genomics Collaborations and Genotyping Technology R&D groups at Affymetrix, Inc. Prior to joining Affymetrix, Dr. Kennedy was a scientific leader for the colon cancer and breast cancer gene discovery efforts at Chiron Corporation, resulting in the identification of oncology markers for therapeutic drug development. Dr. Kennedy was previously a scientist at Millennium Pharmaceuticals, where she implemented genomic and genetic approaches to uncover diabetes susceptibility genes. She holds a Ph.D. degree in biochemistry, and completed postdoctoral training at the University of California at San Francisco in the Biochemistry Department and Hormone Research Institute. Dr. Kennedy has published more than 40 articles in peer-reviewed scientific journals and is a co-inventor on more than 20 patents.

Richard Lanman, MD

Chief Medical Officer Richard Lanman joined Veracyte in 2008 as Chief Medical Officer. He previously served as Executive Vice President and Chief Medical Officer of diaDexus, Inc., where he drove commercialization of PLAC^TM, a molecular diagnostic test for heart attack and stroke risk. Dr. Lanman previously served as Executive Vice President of Corporate Development and Chief Medical Officer at Atherotech, an advanced cardiodiagnostics testing laboratory, where he drove key clinical studies and business development. Prior to Atherotech, Dr. Lanman was Founder and CEO of Adesso, an application service provider profiling quality and utilization for specialist physician networks. Earlier in his career, he was in physician practice management roles as Senior Vice President and Medical Director for San Jose Medical Group, and as a Chief of Quality at Kaiser Permanente.

Robert Monroe, MD, PhD

Vice President, Laboratory Operations and Medical Director Robert Monroe, MD, PhD, joined Veracyte in 2010 as the Medical Director and Vice President of Laboratory Operations. Prior to joining Veracyte, Dr. Monroe served as the Chief Medical Officer of BioImagene (acquired by Ventana Medical Systems, a member of the Roche Group, in 2010), a leading provider of imaging solutions for anatomic pathology and clinical diagnostics. At BioImagene, Dr. Monroe led the company’s efforts to develop software applications for pathologists in the areas of image analysis, telepathology, and whole slide imaging. As the head of clinical and regulatory affairs, Dr. Monroe oversaw BioImagene’s clinical collaborations with leading academic institutions as well as the clinical studies program for imaging hardware and software, culminating in multiple FDA 510(k) clearances. Prior to joining BioImagene, Dr. Monroe served as a Medical Director for Central Coast Pathology (acquired by Sonic Healthcare in 2011) where he led cytopathology and molecular pathology programs. Dr. Monroe is board certified in cytopathology, anatomic pathology and clinical pathology. He holds an MD and a PhD degree in Genetics from Harvard Medical School, and completed residency and fellowship training at Stanford and UCLA.

Mark Spring

Chief Financial Officer Mark Spring joined Veracyte in January 2012 as Chief Financial Officer. He previously served as Senior Vice President, Finance and Chief Financial Officer for Prometheus Laboratories Inc., a privately-held diagnostic and specialty pharmaceutical company with over $500 million of revenues, which was sold to Nestle S.A. in July 2011. Prior to Prometheus, Mr. Spring was Senior Vice President and Chief Financial Officer at Hyperion Therapuetics, Inc., a privately-held specialty biopharmaceutical company. Mr. Spring was also Vice President, Finance and Controller at MedImmune, Inc., which was acquired by AstraZeneca PLC in 2007. He has also held senior finance roles with Baxter International, Inc., Dade Behring Inc., Caremark International Inc. and PricewaterhouseCoopers. Mr. Spring holds a B.A. in Business Administration from Monmouth College and is a Certified Public Accountant.